{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T18:27:32Z","timestamp":1782930452991,"version":"3.54.5"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Foundation","doi-asserted-by":"publisher","award":["NNF20SA0064340"],"award-info":[{"award-number":["NNF20SA0064340"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["atherosclerosis-journal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.atherosclerosis.2025.120471","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T08:06:58Z","timestamp":1754467618000},"page":"120471","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Risk reduction of ASCVD attributed to lowering of remnant cholesterol from statins, fibrates, APOC3 inhibitors, and ANGPTL3 inhibitors: a cohort study"],"prefix":"10.1016","volume":"409","author":[{"given":"Mie","family":"Balling","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otto Gr\u00f8n","family":"Roepstorff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas Alexander","family":"Gerds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anette","family":"Varbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin B\u00f8dtker","family":"Mortensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Langsted","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00f8rge Gr\u00f8nne","family":"Nordestgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1442-4694","authenticated-orcid":false,"given":"Shoaib","family":"Afzal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2025.120471_bib1","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1161\/01.CIR.96.6.1737","article-title":"Heterozygous lipoprotein lipase deficiency: frequency in the general population, effect on plasma lipid levels, and risk of ischemic heart disease","volume":"96","author":"Nordestgaard","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2025.120471_bib2","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1016\/S0140-6736(10)60545-4","article-title":"Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies","volume":"375","author":"Sarwar","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2025.120471_bib3","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/ng.2795","article-title":"Common variants associated with plasma triglycerides and risk for coronary artery disease","volume":"45","author":"Do","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.atherosclerosis.2025.120471_bib4","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1161\/CIRCULATIONAHA.113.003008","article-title":"Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation","volume":"128","author":"Varbo","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2025.120471_bib5","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jacc.2012.08.1026","article-title":"Remnant cholesterol as a causal risk factor for ischemic heart disease","volume":"61","author":"Varbo","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2025.120471_bib6","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S0140-6736(14)61177-6","article-title":"Triglycerides and cardiovascular disease","volume":"384","author":"Nordestgaard","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2025.120471_bib7","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1308027","article-title":"Loss-of-function mutations in APOC3 and risk of ischemic vascular disease","volume":"371","author":"J\u00f8rgensen","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2025.120471_bib8","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1307095","article-title":"Loss-of-function mutations in APOC3, triglycerides, and coronary disease","volume":"371","author":"Crosby","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2025.120471_bib9","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1056\/NEJMoa1507652","article-title":"Coding variation in ANGPTL4, LPL, and SVEP1 and the risk of coronary disease","volume":"374","author":"Stitziel","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2025.120471_bib10","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1001\/jama.2017.0972","article-title":"Association of rare and common variation in the lipoprotein lipase gene with coronary artery disease","volume":"317","author":"Khera","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2025.120471_bib11","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1001\/jama.2018.20045","article-title":"Association of triglyceride-lowering LPL variants and LDL-C-Lowering LDLR variants with risk of coronary heart disease","volume":"321","author":"Ference","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2025.120471_bib12","doi-asserted-by":"crossref","first-page":"3258","DOI":"10.1093\/eurheartj\/ehab705","article-title":"Elevated remnant cholesterol increases the risk of peripheral artery disease, myocardial infarction, and ischaemic stroke: a cohort-based study","volume":"43","author":"Wadstr\u00f6m","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2025.120471_bib13","doi-asserted-by":"crossref","first-page":"4791","DOI":"10.1093\/eurheartj\/ehab551","article-title":"Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the european atherosclerosis society","volume":"42","author":"Ginsberg","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2025.120471_bib14","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1016\/j.jacc.2020.09.610","article-title":"VLDL cholesterol accounts for one-half of the risk of myocardial infarction associated with apoB-Containing lipoproteins","volume":"76","author":"Balling","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2025.120471_bib15","doi-asserted-by":"crossref","first-page":"4186","DOI":"10.1093\/eurheartj\/ehad337","article-title":"Triglyceride-rich lipoprotein remnants, low-density lipoproteins, and risk of coronary heart disease: a UK biobank study","volume":"44","author":"Bj\u00f6rnson","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2025.120471_bib16","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1016\/j.jacc.2022.03.384","article-title":"Elevated remnant cholesterol reclassifies risk of ischemic heart disease and myocardial infarction","volume":"79","author":"Doi","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2025.120471_bib17","doi-asserted-by":"crossref","first-page":"e373","DOI":"10.1161\/ATVBAHA.123.319297","article-title":"Independent causal effect of remnant cholesterol on atherosclerotic cardiovascular outcomes: a mendelian randomization study","volume":"43","author":"Navarese","year":"2023","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.atherosclerosis.2025.120471_bib18","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/joim.13059","article-title":"Contribution of remnant cholesterol to cardiovascular risk","volume":"288","author":"Langsted","year":"2020","journal-title":"J Intern Med"},{"key":"10.1016\/j.atherosclerosis.2025.120471_bib19","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/j.jacc.2024.07.034","article-title":"Quantifying triglyceride-rich lipoprotein atherogenicity, associations with inflammation, and implications for risk assessment using Non-HDL cholesterol","volume":"84","author":"Bj\u00f6rnson","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2025.120471_bib20","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1056\/NEJMoa2404147","article-title":"Zodasiran, an RNAi therapeutic targeting ANGPTL3, for mixed hyperlipidemia","volume":"391","author":"Rosenson","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2025.120471_bib21","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa2404143","article-title":"Plozasiran, an RNA interference agent targeting APOC3, for mixed hyperlipidemia","volume":"391","author":"Ballantyne","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2025.120471_bib22","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1001\/jamacardio.2024.0959","article-title":"Plozasiran (ARO-APOC3) for severe hypertriglyceridemia: the SHASTA-2 randomized clinical trial","volume":"9","author":"Gaudet","year":"2024","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.atherosclerosis.2025.120471_bib23","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2025.120471_bib24","first-page":"e1082","article-title":"AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American college of cardiology\/american heart association task force on clinical practice guidelines","volume":"139","author":"Grundy","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2025.120471_bib25","first-page":"1129","article-title":"Canadian cardiovascular society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults","volume":"37","author":"Pearson","year":"2021","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.atherosclerosis.2025.120471_bib26","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1056\/NEJMoa2210645","article-title":"Triglyceride lowering with pemafibrate to reduce cardiovascular risk","volume":"387","author":"Das Pradhan","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2025.120471_bib27","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1161\/CIRCULATIONAHA.118.033470","article-title":"Relationship of familial hypercholesterolemia and high low-density lipoprotein cholesterol to ischemic stroke: copenhagen general population study","volume":"138","author":"Beheshti","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2025.120471_bib28","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1177\/1403494811401482","article-title":"The Danish national patient register","volume":"39","author":"Lynge","year":"2011","journal-title":"Scand J Publ Health"},{"key":"10.1016\/j.atherosclerosis.2025.120471_bib29","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1177\/1403494811399958","article-title":"The Danish register of causes of death","volume":"39","author":"Helweg-Larsen","year":"2011","journal-title":"Scand J Publ Health"},{"key":"10.1016\/j.atherosclerosis.2025.120471_bib30","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1177\/1403494810387965","article-title":"The Danish civil registration system","volume":"39","author":"Pedersen","year":"2011","journal-title":"Scand J Publ Health"},{"key":"10.1016\/j.atherosclerosis.2025.120471_bib31","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1001\/jama.2013.280532","article-title":"Comparison of a novel method vs the friedewald equation for estimating low-density lipoprotein cholesterol levels from the standard lipid profile","volume":"310","author":"Martin","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2025.120471_bib32","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0197-2456(96)00075-X","article-title":"A note on quantifying follow-up in studies of failure time","volume":"17","author":"Schemper","year":"1996","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.atherosclerosis.2025.120471_bib33","doi-asserted-by":"crossref","first-page":"813","DOI":"10.2307\/2532098","article-title":"Estimates of absolute cause-specific risk in cohort studies","volume":"46","author":"Benichou","year":"1990","journal-title":"Biometrics"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2025.120471_bib34","doi-asserted-by":"crossref","first-page":"440","DOI":"10.32614\/RJ-2017-062","article-title":"riskRegression: predicting the risk of an event using cox regression models","volume":"9","author":"Ozenne","year":"2017","journal-title":"The R Journal"},{"key":"10.1016\/j.atherosclerosis.2025.120471_bib35","series-title":"A language and environment for statistical computing","year":"2024"},{"key":"10.1016\/j.atherosclerosis.2025.120471_bib36","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehac822","article-title":"Elevated remnant cholesterol, plasma triglycerides, and cardiovascular and non-cardiovascular mortality","author":"Wadstr\u00f6m","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2025.120471_bib37","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1161\/ATVBAHA.123.320175","article-title":"Remnant cholesterol, not LDL cholesterol, explains peripheral artery disease risk conferred by apoB: a cohort study","volume":"44","author":"Wadstr\u00f6m","year":"2024","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.atherosclerosis.2025.120471_bib38","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1161\/CIRCRESAHA.115.306249","article-title":"Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology","volume":"118","author":"Nordestgaard","year":"2016","journal-title":"Circ Res"},{"key":"10.1016\/j.atherosclerosis.2025.120471_bib39","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1161\/01.ATV.11.3.569","article-title":"Quantitative studies of transfer in vivo of low density, Sf 12-60, and Sf 60-400 lipoproteins between plasma and arterial intima in humans","volume":"11","author":"Shaikh","year":"1991","journal-title":"Arterioscler Thromb"},{"key":"10.1016\/j.atherosclerosis.2025.120471_bib40","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1161\/01.ATV.12.1.6","article-title":"Influx in vivo of low density, intermediate density, and very low density lipoproteins into aortic intimas of genetically hyperlipidemic rabbits. Roles of plasma concentrations, extent of aortic lesion, and lipoprotein particle size as determinants","volume":"12","author":"Nordestgaard","year":"1992","journal-title":"Arterioscler Thromb"},{"key":"10.1016\/j.atherosclerosis.2025.120471_bib41","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1161\/01.ATV.15.4.534","article-title":"Selective retention of VLDL, IDL, and LDL in the arterial intima of genetically hyperlipidemic rabbits in vivo. Molecular size as a determinant of fractional loss from the intima-inner media","volume":"15","author":"Nordestgaard","year":"1995","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.atherosclerosis.2025.120471_bib42","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1161\/CIRCULATIONAHA.106.676890","article-title":"Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications","volume":"116","author":"Tabas","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2025.120471_bib43","doi-asserted-by":"crossref","DOI":"10.1038\/s41569-024-01111-0","article-title":"Apolipoprotein B-containing lipoproteins in atherogenesis","author":"Bor\u00e9n","year":"2025","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.atherosclerosis.2025.120471_bib44","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1161\/ATVBAHA.111.226100","article-title":"Triglycerides and heart disease: still a hypothesis?","volume":"31","author":"Goldberg","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.atherosclerosis.2025.120471_bib45","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1093\/clinchem\/hvaa296","article-title":"Triglyceride-rich lipoprotein remnants and cardiovascular disease","volume":"67","author":"Duran","year":"2021","journal-title":"Clin Chem"},{"key":"10.1016\/j.atherosclerosis.2025.120471_bib46","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1177\/153537020422900611","article-title":"Differential effects of low-density lipoprotein and chylomicron remnants on lipid accumulation in human macrophages","volume":"229","author":"Batt","year":"2004","journal-title":"Exp Biol Med"},{"key":"10.1016\/j.atherosclerosis.2025.120471_bib47","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1016\/j.jacc.2025.02.035","article-title":"Target populations for novel triglyceride-lowering therapies","volume":"85","author":"Nordestgaard","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2025.120471_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2024.117556","article-title":"Remnant cholesterol, LDL cholesterol, and apoB absolute mass changes explain results of the PROMINENT trial","volume":"393","author":"Doi","year":"2024","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2025.120471_bib49","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1373\/clinchem.2017.279463","article-title":"Remnant cholesterol and myocardial infarction in normal weight, overweight, and Obese individuals from the copenhagen general population study","volume":"64","author":"Varbo","year":"2018","journal-title":"Clin Chem"},{"key":"10.1016\/j.atherosclerosis.2025.120471_bib50","doi-asserted-by":"crossref","DOI":"10.1007\/s00125-023-06016-0","article-title":"Elevated remnant cholesterol and atherosclerotic cardiovascular disease in diabetes: a population-based prospective cohort study","author":"Wadstr\u00f6m","year":"2023","journal-title":"Diabetologia"},{"key":"10.1016\/j.atherosclerosis.2025.120471_bib51","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1161\/ATVBAHA.124.321387","article-title":"Impaired renal function with higher remnant cholesterol related to risk of atherosclerotic cardiovascular disease: a cohort study","volume":"44","author":"El\u00edas-L\u00f3pez","year":"2024","journal-title":"Arterioscler Thromb Vasc Biol"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915025013693?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915025013693?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T13:36:58Z","timestamp":1772804218000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915025013693"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":51,"alternative-id":["S0021915025013693"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2025.120471","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk reduction of ASCVD attributed to lowering of remnant cholesterol from statins, fibrates, APOC3 inhibitors, and ANGPTL3 inhibitors: a cohort study","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2025.120471","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"120471"}}